OBJECTIVES:

Atezolizumab plus bevacizumab (AtezBeva) treatment was approved for unresectable hepatocellular carcinoma (HCC) patients. Previous evidence demonstrated that the characteristics between real-world and trial patients were different. Therefore, this study aimed to evaluate the real-world effectiveness of AtezBeva in unresectable HCC patients.

METHODS:

We analyzed the electronic medical records (EMR) data from a multi-institution in north Taiwan. The HCC patients who received AtevBeva as first-line systemic treatment from July 2018 to December 2020 were included in our study. We followed patients from the first date of AtevBeva treatment until disease progressed, death, loss of follow-up, or May 2022. The clinical outcomes were tumor response according to modified Response Evaluation Criteria in Solid Tumors (mREICT), progression-free survival (PFS) and overall survival (OS).

RESULTS:

We identified a cohort of 31 HCC patients newly receiving the AtevBeva. The mean age of patients was 58.0 (SD 11.0) and 65% of patients were male in our study. The 61% of HCC patients were Barcelona Clinic Liver Cancer (BCLC) stage C, and 81% were classified as Child-Pugh A. After AtevBeva treatment, the objective response rate (ORR) and disease control rate (DCR) were 25.8% and 64.2%, respectively. In Kaplan-Meier analysis, we found that median PFS and OS was 11.3 and 17.1 months, respectively.

CONCLUSIONS:

The ORR was similar between clinical trial and real-world. However, the DCR in real-world patients was relatively worsen compared with trial patients. We considered the difference may be attribute to poorer liver function in real-world patients. The effectiveness of AtevBeva treatment in real-world still need further discussion.